BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models
about
The multifaceted role of lysine acetylation in cancer: prognostic biomarker and therapeutic targetCell Proliferation in NeuroblastomaKeep-ING balance: tumor suppression by epigenetic regulationCancer epigenetics drug discovery and development: the challenge of hitting the markTargeting bromodomains: epigenetic readers of lysine acetylationInhibition of BET bromodomains as a therapeutic strategy for cancer drug discoveryTargeting BET bromodomains for cancer treatmentDrug Discovery Targeting Bromodomain-Containing Protein 4.Manifestations of gastrointestinal plasmablastic lymphoma: a case series with literature reviewCDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer.Use of epigenetic drugs in disease: an overview.An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinomaThe biology of castration-resistant prostate cancerTop2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.Alternative modulation of protein-protein interactions by small moleculesBRD4 Structure-Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536Bromodomain and extraterminal inhibition blocks tumor progression and promotes differentiation in neuroblastomaMapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk.BET inhibition as a new strategy for the treatment of gastric cancer.The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs.MEDICI: Mining Essentiality Data to Identify Critical Interactions for Cancer Drug Target Discovery and Development.Chromatin deregulation in disease.Epigenetics in cancer stem cells.Rapid and Reliable Binding Affinity Prediction of Bromodomain Inhibitors: A Computational Study.Bromodomain and Extra-Terminal Protein Inhibition Attenuates Neutrophil-dominant Allergic Airway Disease.Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1.MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.Bromodomains and their pharmacological inhibitors.Epigenetic pathway targets for the treatment of disease: accelerating progress in the development of pharmacological tools: IUPHAR Review 11.A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis.Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial.Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations.Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds.Environmental toxicants, incidence of degenerative diseases, and therapies from the epigenetic point of view.Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer.Histone Modifications and Cancer.Protein-protein interaction inhibitors: advances in anticancer drug design.Bromodomain and extraterminal protein inhibitors in pediatrics: A review of the literature.Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer.
P2860
Q26744292-F4619336-52E2-4967-8814-1ED32FB61301Q26771708-F7252E78-31E9-417D-9864-DC6F26B843CCQ26859017-4D1208CD-97D5-4D1B-A779-2F8997A7BACEQ27002333-E643090E-EC6F-47DF-A2F2-C27BE93347F0Q28238635-2518F262-5D62-458D-9A66-03C017A091B5Q28260105-A911367E-F47B-4E08-B613-95571DC2D5F7Q28263519-4CBA5618-0ED2-4578-84F3-A39B05519785Q30352390-F600D46E-0AF4-43E6-BAD8-34C2B8F787E6Q34137455-A86EEA67-7E4E-4364-9DAB-C0E54694D23CQ34449062-18EA7491-C72F-499F-BA3E-0E28A54C39B1Q34607095-1381E81D-D16D-4AC8-9391-96B05D5021DBQ34926232-3C172CD8-7F98-4C56-BF79-2E7321367D33Q35039889-B78C512A-DECA-47AE-83E5-412C456C87D2Q35550192-159A1BCA-9A2A-4B5A-BF4E-B51632600566Q35620999-16FB9725-1673-43C3-AF8D-A61493BD9A42Q35697342-DD0A95B4-D788-414A-9BA8-6D7856521EDDQ35952249-30176CF9-1192-4766-A23D-A51EA7C285BAQ36012341-C2EFA2E8-11CC-40B6-BB73-64737F16D4ECQ36040347-5B47E083-F5E9-4E98-8BCA-26B4E91FCD35Q36169695-971F1C87-F337-4EE8-97C5-44DA2DEC5213Q36258723-667BFEB8-8673-437E-B220-84FBFDDE76E5Q36599581-13445141-A29B-4C4C-BA03-3797C4A87410Q37618640-AE5638B9-2C36-47BA-90B7-D01A37808160Q37646303-A7C196B4-F165-4673-BF14-2B9C2182980DQ37663035-FAB52862-B812-42BA-BF28-B00B4116444DQ37691709-8FF17DD1-F677-4C0D-A3CB-BA9C8E16FF46Q37718370-DBC45454-5988-48B7-B3D0-C93D51821071Q38185355-D7DF0331-CA32-4B91-BCF9-231C6E29CA44Q38233723-9BD7087F-BD89-4F13-8BCB-95868D39B6BEQ38295876-FC2DB9A9-03DA-4A87-B439-62077FD25460Q38371672-FEB0CF27-C70B-433A-A812-8C2018D21EFBQ38542092-8287DCAC-13D4-4E3E-B0C0-8B8C0EEFA691Q38625880-368D180B-3C66-41DE-BCC2-FDA766BC536DQ38673230-B029560A-2AC6-4EF5-ACF9-A07417CE362FQ38682574-AF849B49-3AFA-4D91-94E3-346EEBDEA1A7Q38741165-E9045B62-039F-4B49-97F6-438EB6C3D220Q38796064-1841F92F-55F1-4CD8-B0E7-5F8AEAF36D4AQ38935390-649CA9BD-0226-4A9B-9B79-11FC2CC0E330Q39024306-DBB72C55-ADDF-436F-ADDC-93B8DB1912C6Q39051416-33E2BA75-DAE6-4AFC-9833-6A92A109E9E5
P2860
BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
BET Inhibition Silences Expres ...... in Neuroblastoma Tumor Models
@ast
BET Inhibition Silences Expres ...... in Neuroblastoma Tumor Models
@en
BET Inhibition Silences Expres ...... in Neuroblastoma Tumor Models
@nl
type
label
BET Inhibition Silences Expres ...... in Neuroblastoma Tumor Models
@ast
BET Inhibition Silences Expres ...... in Neuroblastoma Tumor Models
@en
BET Inhibition Silences Expres ...... in Neuroblastoma Tumor Models
@nl
prefLabel
BET Inhibition Silences Expres ...... in Neuroblastoma Tumor Models
@ast
BET Inhibition Silences Expres ...... in Neuroblastoma Tumor Models
@en
BET Inhibition Silences Expres ...... in Neuroblastoma Tumor Models
@nl
P2093
P2860
P3181
P1433
P1476
BET Inhibition Silences Expres ...... in Neuroblastoma Tumor Models
@en
P2093
Anastasia Wyce
BaoChau Le
Charles F McHugh
Chun-Wa Chung
Dashyant Dhanak
Gopinath Ganji
Karen M Kennedy-Wilson
Kimberly N Smitheman
Kurt R Auger
Lydia V Sanchez
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0072967
P407
P577
2013-01-01T00:00:00Z